Biological Response Modifiers

  • Robert K. Oldham
Part of the Cancer Growth and Progression book series (CAGP, volume 10)


Biotherapy represents a new modality of cancer treatment. It utilizes biologicals and biological response modifiers. Many of these substances are of ‘natural’ origin eminating from mammalian cells as physiologic mediators of immune response and as substances active in the regulation of growth and maturation. With the advent of molecular biological techniques, hybridoma technology and computer applications, it is now possible to prepare these biological substances in highly purified form and in large quantities for use as medicinals. The expertise required to apply these biotherapeutic approaches to the treatment of cancer often involves the use of immunological and/or molecular biological capabilities. Because of the rather specialized expertise needed to understand and apply these substances as anticancer approaches, those individuals with expertise in the application of chemotherapy to patients with cancer are not necessarily well prepared for the translation of biotherapy to the clinic. Biotherapeutic approaches are broad and involve a whole range of physiological responses inherent in cancer biology. The approaches needed to bring these biotherapeutic capabilities to the clinic need to be considered carefully and the use of new techniques and new methods of application should be encouraged so as not to inhibit these potentially powerful anticancer approaches. As natural mediators, many biologicals have much less inherent toxicity than the drugs previously used in systemic cancer therapy. Therefore, the systems for translating these substances from the laboratory to the clinic should be restructured for the rapid translation of biotherapy to the patient.


Tumor Associate Antigen Biological Response Modifier Monoclonal Antibody Therapy Animal Tumor Model Brucella Abortus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexander P: Back to the drawing board: The need for more realistic model systems for immunotherapy. Cancer 40: 469, 1977CrossRefGoogle Scholar
  2. 2.
    Baldwin RW: Relevant animal models for immunotherapy. Cancer Immunol Immunother 1: 97, 1976CrossRefGoogle Scholar
  3. 3.
    Bernhard MI, Foon KA, Oeltmann TN, Key ME, Hwang KM, Clark GC, Christensen WL, Hoyer LC, Hanna MG Jr. Oldham RK: Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res 43: 4420, 1983PubMedGoogle Scholar
  4. 4.
    Boss BD, Langman R, Trowbridge I, Dulbecco R. (eds) Monoclonal Antibodies and Cancer. Academic Press, 1983Google Scholar
  5. 5.
    Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winker CF, Veach SR, Zeffren J, Sherwin SA, Oldham RK: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Annals oflnt Med 101: 484, 1984Google Scholar
  6. 6.
    Cheever MA, Greenberg PD, Fefer A: Potential for specific cancer therapy with immune T lymphocytes. J Biol Resp Modif 3: 113, 1984Google Scholar
  7. 7.
    De Vita VT: Progress in cancer management: Keynote address. Cancer 51: 2401, 1983CrossRefGoogle Scholar
  8. 8.
    De Vita VT: The relationship between tumor mass and resistance to chemotherapy: implication for surgical adjuvant treatment of cancer. Cancer 51: 1209, 1983CrossRefGoogle Scholar
  9. 9.
    Dillman RO, Beauregard JC, Mendelsohn J. et al: Phase I trials of thymosin fraction 5 and thymosin alpha-1. J Biol Resp Modif 1: 35, 1982Google Scholar
  10. 10.
    Evans CH: Lymphotoxin-an immunologic hormone with anti-carcinogenic and antitumor activity. Cancer Immunol Immunother 12: 181, 1982CrossRefGoogle Scholar
  11. 11.
    Fidler IJ, Gersten DM, Budman MB: Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 36: 3160, 1976PubMedGoogle Scholar
  12. 12.
    Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 28: 149, 1978PubMedCrossRefGoogle Scholar
  13. 13.
    Fidler IJ, Berendt M, Oldham RK: The rationale for and design of screening assays for the assessment of biological response modifiers for cancer treatment. J Biol Resp Modif 1: 15, 1982Google Scholar
  14. 14.
    Foon KA, Bernhard MI, Oldham RK: Monoclonal antibody therapy: assessment by animal tumor models. J Biol Resp Modif 1: 277, 1982Google Scholar
  15. 15.
    Foon KA, Schroff R, Bunn PA, Mayer D, Abrams PG, Fer MF, Ochs J, Bottino G, Sherwin SA, Carlo DJ, Herberman RB, Oldham RK: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64: 1085, 1984PubMedGoogle Scholar
  16. 16.
    Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe E, Oldham RK: Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. New England J of Med 311: 1148, 1984CrossRefGoogle Scholar
  17. 17.
    Goldstein AL, and Chirigos MA: In: Progress in Cancer Research and Therapy, Vol. 20, pp. 1–324, Raven Press, New York, 1982Google Scholar
  18. 18.
    Hanna MG Jr, Key ME, Oldham RK: Biology of cancer therapy: Some new insights into adjuvant treatment of metastatic solid tumors. J Biol Resp Modif 4: 295, 1983Google Scholar
  19. 19.
    Hanna MG Jr, Brandhorst JS, Peters LC: Active specific immunotherapy of residual micrometastasis: an evaluation of sources, doses and ratios of BCG with tumor cells. Cancer Immunollmmunother 7: 165, 1979Google Scholar
  20. 20.
    Hanna MG Jr, Key ME. Immunotherapy of metastases enhances subsequent chemotherapy. Science 217: 367, 1982PubMedCrossRefGoogle Scholar
  21. 21.
    Herberman RB, Counterpoint: Animal tumor models and their relevance to human tumor immunology. J Biol Resp Modif 2: 39, 1982Google Scholar
  22. 22.
    Hewitt HB: Animal tumor models and their relevance to human tumor immunology. J Biol Resp Modif 1:107, 1982Google Scholar
  23. 23.
    Hwang KM, Foon KA, Cheung PH, Pearson JW, Oldham RK: Selective antitumor effect on L-10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatome-associated antigen. Cancer Res 44: 4578, 1984PubMedGoogle Scholar
  24. 24.
    Key ME, Bernhard MI, Hoyer LC, Foon KA, Oldham RK, and Hanna MG JR: Guinea pig 10 hepatocarcinoma model for monoclonal antibody serotherapy: In vivo localization of a monoclonal antibody in normal and malignant tissues. J Immunol 139: 1451, 1983Google Scholar
  25. 25.
    Key ME, Brandhorst JS, Hanna MC Jr: Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer. J Immunol 130: 2987, 1983PubMedGoogle Scholar
  26. 26.
    Kirkwood JM, Ernstoff MS: Interferon in the treatment of human cancer. J Clin Oncol 2: 336, 1984PubMedGoogle Scholar
  27. 27.
    Kripke ML, Fisher MS: Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer Inst 57: 211, 1976PubMedGoogle Scholar
  28. 28.
    Kripke ML, Lofgreen JS, Beard J, Jessup JM, Fisher MS: In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation. J Natl Cancer Inst 59: 1227, 1977PubMedGoogle Scholar
  29. 29.
    McCormick DL, Adamowski CB, Fiks A, Moon RC: Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res 41: 1690, 1981PubMedGoogle Scholar
  30. 30.
    Miller FR, Heppner GH: Immunologic heterogenicity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst 63: 1457, 1979PubMedGoogle Scholar
  31. 31.
    Oldham RK: Biological response modifier program J Biol Resp Modif 1: 81, 1982Google Scholar
  32. 32.
    Oldham RK: Monoclonal antibodies in cancer therapy. J of Clin Onc 1: 582, 1983Google Scholar
  33. 33.
    Oldham RK: Biologicals: New horizons in pharmaceutical development. J Biol Resp Modif 2: 199, 1983Google Scholar
  34. 34.
    Oldham RK: Biologicals and biological response modifiers: New strategies for clinical trials. In: Interferon IV, edited by Finter NB, Oldham RK. Amsterdam Elsevier Biomedical Press, 1984Google Scholar
  35. 35.
    Oldham RK: In: Interferon VI. edited by Burke D, Cantrell K, Gresser I, De Maeyer E, Landy M, Revel M, Vilcek J. New York Academic Press, 1984Google Scholar
  36. 36.
    Oldham RK (ed.): In vivo effects of Interleukin 2. J Biol Resp Modif 3:455, 1984Google Scholar
  37. 37.
    Oldham RK: Biologicals and biological response modifiers: The fourth modality of cancer treatment. Cancer Treat Rep 68: 221, 1984PubMedGoogle Scholar
  38. 38.
    Oldham RK, and Smalley RV: Immunotherapy: The old and the new. J Biol Resp Modif 2: 1, 1983Google Scholar
  39. 39.
    Oldham RK and Smalley RV: The role of interferon in the treatment of cancer. In: Interferon: Research, Clinical Application and Regulatory Consideration, edited by Zoon KT, Noguchi PC, Liu TY, pp. 191–205. Elsevier Science Publishing, 1984Google Scholar
  40. 40.
    Oldham RK, Thurman GB, Talmadge JE, Stevenson HC, Foon KA: Lymphokines, monoclonal antibodies and other biological response modifiers in the treatment of cancer. Cancer 54: 2795, 1984PubMedCrossRefGoogle Scholar
  41. 41.
    Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG, Fer M, Schoenberger CS, Farrell M, Kimball E, Sherwin SA: Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Onc 2: 1235, 1984Google Scholar
  42. 42.
    Oldham RK: The role of biological response modifiers in the therapy of cancer: An overview. Natural Immunity Symposium (Hawaii ), 1985Google Scholar
  43. 43.
    Oldham RK, Abrams P: Monoclonal Antibody Therapy of Solid Tumors. Dordrecht Martinus Nijhoff Publishers, 1985Google Scholar
  44. 44.
    Oldham RK: Biological response modifiers, In: Introduction, Torrence, PF, (eds.) Biological Response Modifiers, edited by Torrence PF. Academic Press, New York, 1984Google Scholar
  45. 45.
    Rosenau W: Lymphotoxin: properties, role and mode of action. Int J Immunopharm 3: 1, 1981CrossRefGoogle Scholar
  46. 46.
    Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger CS, Maluish AE, Oldham RK: A multiple dose Phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248: 2461, 1982PubMedCrossRefGoogle Scholar
  47. 47.
    Smalley RV, Oldham RK: Biological response modifiers: pre-clinical evaluation and clinical activity. CRC Crit Rev in Oncol Hemat 1: 259, 1984CrossRefGoogle Scholar
  48. 48.
    Smalley RV, Talmadge JA, Oldham RK, Thurman GB: The thymosins: preclinical and clinical studies with fraction V and alpha-1. Cancer Treat Rev 11: 69, 1984PubMedCrossRefGoogle Scholar
  49. 49.
    Stevenson HC, Ochs JJ, Halverson L, Oldham RK, Sherwin SA, Foon KA: Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma, Dramatic responses with resolution of pulmonary complications. Am J Med 77: 355, 1984PubMedCrossRefGoogle Scholar
  50. 50.
    Sugarbaker EV, Cohen AM: Altered antigenicity of spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery 73: 155, 1972Google Scholar
  51. 51.
    Terry MD, Rosenberg SA (eds.): Immunotherapy of Cancer, pp. 1–398. Excerpta Medica, New York, 1982Google Scholar

Updated References

  1. Oldham RK (ed): Principals of Cancer Biotherapy. New York, Raven Press, 502pp., 1987Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Robert K. Oldham

There are no affiliations available

Personalised recommendations